Epix and Mallinckrodt link with Siemens:
This article was originally published in Clinica
Executive Summary
Siemens Medical Systems, Epix Medical and Mallinckrodt are to collaborate on developing contrast-based cardiovascular magnetic resonance imaging (MRI) technologies. The collaboration will combine AngioMark-enhanced MRI with advanced imaging and three-dimensional computerised visualisation technologies. AngioMark, Epix and Mallinckrodt's intravascular contrast agent, is currently in Phase II trials for detecting aorto-iliac occlusive disease.
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.